Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
ATLANTA, Feb. 29, 2016 -- Alimera Sciences (NASDAQ:ALIM), a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the 36th Annual Cowen Healthcare Conference, to be held March 7-9, 2016 at the The Boston Marriott Copley Place, Boston, Massachusetts. Alimera Sciences' presentation will take place Wednesday, March 9, 2016 at 8:00 AM Eastern Time.
A live broadcast of the conference presentation will be available. To access the broadcast, go to the "Investor Relations" section of the Company's website at www.alimerasciences.com. A replay of the conference presentation will also be available.
About Alimera Sciences
Alimera Sciences (NASDAQ:ALIM) (Alimera), founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases.
For more information, please visit www.alimerasciences.com.
COCKRELL GROUP 877.889.1972 [email protected] cockrellgroup.com
